

Keystone Symposia: Advances in Biopharmaceuticals

Sponsored by Alnylam Pharmaceuticals, Inc. and Pfizer Global Research & Development

January 8–13, 2009 • Zermatt Resort & Spa • Midway, Utah • USA

Scientific Organizers: John M. McPherson and Thomas F. Bumol

PROGRAM FACULTY & TALKS

Patrick A. Baeuerle, Micromet, Inc., USA

Cancer Therapy by T Cell-Engaging BiTE Antibodies

C. Frank Bennett, ISIS Pharmaceuticals, Inc., USA

Progress in Antisense Therapeutics

Francis J. Castellino, University of Notre Dame, USA

Anticoagulant Protein C Resides at the Crossroads of Hemostasis and Inflammation

Lucienne Chatenoud, INSERM, Hopital Necker, France

Restoration of Self Tolerance in Autoimmune Diabetes

Alasdair Coles, University of Cambridge, UK

Anti-CD52 Antibodies for Treatment of Multiple Sclerosis

Elisabeth de Vries, Universitair Medisch Centrum Groningen, Netherlands

Use of Zirconium-89 Labeled Antibodies for Tumor Imaging:

Possible Applications for Guided Targeted Tumor Therapy

Ronald B. DeMattos, Lilly Research Laboratories, USA

Abeta Immunotherapy: The Development of Compound Specific Biomarkers to Aid the Translation of Preclinical to Clinical Studies

John R. Desjarlais, Xencor, USA

Creating Novel and Enhanced Antibody Therapeutics through Fc Engineering

Napoleone Ferrara*, Genentech, Inc., USA

VEGF-Dependent and -Independent Angiogenesis

Tillman U. Gerngross, Dartmouth College, USA

Adimab's Human Antibody Discovery Platform:

A New Benchmark for Antibody Discovery Technologies

Antonio Gualberto, Pfizer Onc, USA

Development of Figitumumab (CP-751,871) a Fully Human Monoclonal Antibody against IGF-1R

Bart Keymeulen, Vrije Universiteit Brussel, Belgium

Preservation of Beta Cell Function in Human Type 1 Diabetes

Alexei Kharitonov, Eli Lilly and Company, USA

FGF-21 and its Novel Variants to Treat Metabolic Disorders

Kristine Kikly, Eli Lilly and Company, USA

Anti-BAFF for the Treatment of RA

C. Randal Mills, Osiris Therapeutics, Inc., USA

Mesenchymal Stem Cells for Treatment of GVHD

Clark Pan, Genzyme Corporation, USA

Carbohydrate Engineering of Acid α -Glucosidase for Treatment of Pompe Disease

Marco A. Passini, Genzyme Corporation, USA

Gene and Antisense Oligonucleotide Therapies for Spinal Muscular Atrophy

Sushil G. Rane, National Institutes of Health, USA

Protection from Obesity and Diabetes by Blockade of TGF- β /Smad3 Signaling

Michael Reiss, Robert Wood Johnson Medical School, USA

TGF- β as a New Cancer Therapy Target

Richard Ross, Asterion, UK

Hormone/Hormone Receptor Fusion Proteins for Improving the Pharmacokinetic/Pharmacodynamic Properties of Hormone Replacement Therapies

Dinah Sah, Alnylam Pharmaceuticals Inc., USA

Development of RNAi Therapeutics

Volker Schellenberger, Amunix, Inc., USA

Protein Pharmaceuticals Comprising an XTEN Half-Life Extension Module

Peter D. Senter, Seattle Genetics Inc., USA

Treatment of Hodgkin's Lymphoma with SGN-35, a Potent Antibody Drug Conjugate

W. David Shen, Merck

From Mammalian Cell Display to Cross-Species Display of Antibodies

Scott Simonet, Amgen Inc., USA

OPG/RANKL and Sclerostin; Physiological Regulators of Bone Density; Targets for The Treatment of Bone Loss Indications

Matthew Sleeman, MedImmune, USA

Antibody Structure Function Relationships

James M. Wilson, University of Pennsylvania, USA

Gene Therapy: Lessons Learned and Opportunities for the Future

Chengbin Wu, Abbott Bioresearch Center, USA

Protein Engineering of DVD-Ig:

Focusing on Pharmacokinetics, Manufacturing and Preformulation Studies

George D. Yancopoulos, Regeneron Pharmaceuticals, Inc., USA

From Traps for VEGF and IL-1 Traps to VelocImmune, a New Genetically Humanized Mice for Generating Fully Human Antibodies

*Keynote speaker. Program subject to change. Current as of November 4, 2009.



This meeting will contain eight sessions covering both biotechnology discovery platforms supporting biopharmaceutical product research and development (four sessions) and specific disease areas where biopharmaceuticals either have or are likely to have a major positive impact on clinical outcomes for patients (four sessions).

PROGRAM PLENARY SESSIONS:

- Antibody Discovery and Engineering
- Protein and Peptide Engineering
- Next Generation Protein-Based Biopharmaceuticals
- Nucleic Acid-Based Biopharmaceuticals
- Cancer and Cancer Supportive Care
- Immune-Mediated Diseases/Transplant
- Diabetes
- Metabolic and Neurological Disorders

DEADLINES:

Early Registration: November 5, 2009

www.keystonesymposia.org/10A2

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

PO Box 1630 • Silverthorne, CO 80498 • USA
www.keystonesymposia.org • 1-800-253-0685 • 1-970-262-1230